NMD4C Early Career Award Nominations Extended

We have extended the nomination submission deadline for our NMD4C Early-Career Investigator Awards! The new deadline is January 13th, 2023.

This initiative will allow NMD4C early-career members to be nominated for one of four awards, celebrating excellence and contribution to the neuromuscular field in both clinical and basic science streams.

The four early-career award categories that will be awarded for 2022 are:

  • Early Career Researcher of the Year (Biomedical)
  • Early Career Researcher of the Year (Clinical)
  • Publication of the Year (Biomedical)
  • Publication of the Year (Clinical)

If you wish to nominate yourself or an individual for any of these awards, please submit the following information via the nomination form here: https://www.surveymonkey.ca/r/NMD4C-ECawards.

You will be asked to include:

  1. Category for which you are nominating the individual.
  2. Brief bio sketch of the nominee. (any kind of biosketch accepted)
  3. Up to three clinical or research milestones of the nominee.
  4. Brief paragraph highlighting the achievements of the individual, and why you think they should receive the award.
  5. (For publication of the year biomedical/clinical) A PDF copy of the full publication you wish to nominate. *Publications from November 2021 – Present will be eligible.

Please complete this nomination form before the deadline of January 13, 2023 at 11:59pm ET.

The awards will be announced in January 2023 alongside the NMD4C/MDC neuromuscular clinical and postdoctoral research fellowships. If you have any questions, please feel free to reach out to communications coordinator James Davis at !

To be eligible for this award you must fall within the CIHR early-career criteria as being within five years of the date of a first independent appointment, and be a member of the NMD4C (if you are not a member, you can sign up here!)

NMD4C launches early career awards for 2022.

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.